MX2019014489A - Programa de dosificacion para tesetaxel y capecitabina. - Google Patents

Programa de dosificacion para tesetaxel y capecitabina.

Info

Publication number
MX2019014489A
MX2019014489A MX2019014489A MX2019014489A MX2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A
Authority
MX
Mexico
Prior art keywords
capecitabine
tesetaxel
dosing schedule
patient
cancer
Prior art date
Application number
MX2019014489A
Other languages
English (en)
Inventor
Kevin Tang
Thomas Wei
Stew Kroll
John G Lemkey
Steven Pfeiffer
Jeff Vacirca
Original Assignee
Odonate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odonate Therapeutics Inc filed Critical Odonate Therapeutics Inc
Publication of MX2019014489A publication Critical patent/MX2019014489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación provee métodos para tratar un paciente con cáncer, como cáncer de mama metastásico, que comprende administrar tesetaxel y capecitabina al paciente.
MX2019014489A 2017-06-02 2018-06-01 Programa de dosificacion para tesetaxel y capecitabina. MX2019014489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514483P 2017-06-02 2017-06-02
PCT/US2018/035653 WO2018223029A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Publications (1)

Publication Number Publication Date
MX2019014489A true MX2019014489A (es) 2020-08-17

Family

ID=64455637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014489A MX2019014489A (es) 2017-06-02 2018-06-01 Programa de dosificacion para tesetaxel y capecitabina.

Country Status (14)

Country Link
US (1) US20200179427A1 (es)
EP (1) EP3630091A4 (es)
JP (1) JP2020522568A (es)
KR (1) KR20200014880A (es)
CN (1) CN111032035A (es)
AU (1) AU2018275122A1 (es)
BR (1) BR112019025164A2 (es)
CA (1) CA3065783A1 (es)
EA (1) EA201992852A1 (es)
IL (1) IL270973A (es)
MA (1) MA50039A (es)
MX (1) MX2019014489A (es)
TW (1) TW201902473A (es)
WO (1) WO2018223029A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210091713A (ko) * 2018-10-17 2021-07-22 오더네이트 테라퓨틱스, 잉크. 테세탁셀로 cns 종양을 치료하는 방법
WO2021034335A1 (en) * 2019-08-16 2021-02-25 Odonate Therapeutics, Inc. Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201701880A (zh) * 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法

Also Published As

Publication number Publication date
EA201992852A1 (ru) 2020-03-27
US20200179427A1 (en) 2020-06-11
CN111032035A (zh) 2020-04-17
EP3630091A4 (en) 2021-03-10
AU2018275122A1 (en) 2019-12-19
TW201902473A (zh) 2019-01-16
CA3065783A1 (en) 2018-12-06
KR20200014880A (ko) 2020-02-11
BR112019025164A2 (pt) 2020-06-16
EP3630091A1 (en) 2020-04-08
WO2018223029A1 (en) 2018-12-06
IL270973A (en) 2020-01-30
JP2020522568A (ja) 2020-07-30
MA50039A (fr) 2020-07-08

Similar Documents

Publication Publication Date Title
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
GEP20217331B (en) Anti-tigit antibodies
MX2020006668A (es) Anticuerpos para lilrb2.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
PH12016500137B1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MY180257A (en) Bifunctional cytotoxic agents
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MX2015010312A (es) Metodos para tratamiento del melanoma.
MY178726A (en) Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
MX2016004678A (es) Composiciones para el tratamiento del cancer.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2023012451A (es) Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer.
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
MX2019002925A (es) Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
MX2017014436A (es) Compuestos biciclicos.
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2019014489A (es) Programa de dosificacion para tesetaxel y capecitabina.